Cel-Sci Corporation Common Stock (NY:CVM)

1.590 -0.050 (-3.05%)

Official Closing Price Updated: 6:30 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cel-Sci Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 22, 2025

Via Benzinga

Why Urban Outfitters Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket ↗

May 22, 2025

Via Benzinga

CEL-SCI Announces Pricing of Public Offering

May 21, 2025

From CEL-SCI Corporation

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

May 21, 2025

Via Benzinga

CEL-SCI Announces Proposed Public Offering

May 21, 2025

From CEL-SCI Corporation

Via Business Wire

CEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia

May 21, 2025

From CEL-SCI Corporation

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

May 20, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

May 20, 2025

Via Benzinga

These stocks are moving in today's session ↗

May 20, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

CEL-SCI Announces Combination of Common Stock

May 19, 2025

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results

May 15, 2025

From CEL-SCI Corporation

Via Business Wire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

May 02, 2025

Via Benzinga

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

April 23, 2025

From CEL-SCI Corporation

Via Business Wire

Which stocks are moving on Monday? ↗

April 14, 2025

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

April 14, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

April 11, 2025

Via Benzinga

New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI’s Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

April 08, 2025

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

March 24, 2025

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Announces Closing of $2.5 Million Offering

March 18, 2025

From CEL-SCI Corporation

Via Business Wire

Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket ↗

March 18, 2025

Via Benzinga

CEL-SCI Announces Pricing of $2.5 Million Offering

March 17, 2025

From CEL-SCI Corporation

Via Business Wire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

March 17, 2025

Via Benzinga

CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine

March 17, 2025

From CEL-SCI Corporation

Via Business Wire

Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

March 14, 2025

From CEL-SCI Corporation

Via Business Wire

Stay updated with the stocks that are on the move in today's pre-market session. ↗

February 20, 2025

As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

February 20, 2025

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

February 18, 2025

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

January 14, 2025

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Announces Closing of $5 Million Offering

December 31, 2024

From CEL-SCI Corporation

Via Business Wire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

December 30, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.